

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mohammad R. Marzabadi, et al.
Serial No.: Not Yet Known
Filed : Herewith
For : SELECTIVE MELANIN CONCENTRATING HORMONE-1
(MCH1) RECEPTOR ANTAGONISTS AND USES
THEREOF

1185 Avenue of the Americas
New York, New York 10036
April 14, 2004

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following reference which is listed on the attached Form PTO-1449 (**Exhibit A**):

1. U.S. Serial No. 09/899,635, filed July 5, 2001, Lagu, et al.

A copy of this application is enclosed as **Exhibit 1**. Applicants request that this application be considered and made of record.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit A**) and which were previously

Mohammad R. Marzabadi, et al.
Application No: Not Yet Known
Filed: Herewith
Page 2

submitted or cited in connection with the prosecution of U.S. Serial No. 09/899,635 from which the subject application claims priority under 35 U.S.C. §120. According to 37 C.F.R. § 1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Patent Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement.

1. U.S. Patent No. 4,438,117, issued March 20, 1984,
Cherkofsky, et al;
2. U.S. Patent No. 4,684,655, issued August 4, 1987, Atwal,
et al;
3. U.S. Patent No. 4,684,656, issued August 4, 1987, Atwal,
et al;
4. U.S. Patent No. 4,684,653, issued August 4, 1987, Taylor,
et al;
5. U.S. Patent No. 4,703,120, issued October 27, 1987, Press,
et al;
6. U.S. Patent No. 4,728,652, issued March 1, 1988, Atwal,
et al;
7. U.S. Patent No. 4,845,216, issued July 4, 1989, Taylor,
et al;
8. U.S. Patent No.: 4,855,301, issued August 8, 1989, Atwal,
et al;

Mohammad R. Marzabadi, et al.
Application No: Not Yet Known
Filed: Herewith
Page 3

9. U.S. Patent No. 4,882,334, issued November 21, 1989,
Shih, et al;
10. U.S. Patent No. 4,902,796, issued February 20, 1990,
Taylor, et al;
11. U.S. Patent No. 4,946,846, issued August 7, 1990, Nomura,
H., et al;
12. U.S. Patent No. 5,134,145 issued July 28, 1992, Brouwer,
et al;
13. U.S. Patent No. 5,149,810, issued September 22, 1992,
Perrior, et al;
14. U.S. Patent No. 5,202,330, issued April 13, 1993, Atwal,
et al;
15. U.S. Patent No. 5,250,531, issued October 5, 1993,
Cooper, et al;
16. U.S. Patent No. 5,292,740, issued March 8, 1994, Burri,
et al;
17. U.S. Patent No. 5,521,189, issued May 28, 1996, Boykin,
et al;
18. U.S. Patent No. 5,541,186, issued July 30, 1996, Breu, et
al;
19. U.S. Patent No. 5,500,424, issued March 19, 1996,
Nagamine, et al;

Mohammad R. Marzabadi, et al.
Application No: Not Yet Known
Filed: Herewith
Page 4

20. U.S. Patent No. 5,594, 141, issued January 14, 1997,
Yuan, et al;
21. U.S. Patent No. 5,942,517, issued August 24, 1999,
Nagarathnam, et al;
22. PCT International Application No. WO 92/00741, published
January 23, 1992;
23. PCT International Application No. WO 92/14453, published
September 3, 1992;
24. PCT International Application No. WO 94/10989, published
May 26, 1994;
25. PCT International Application No. WO 94/22829, published
October 13, 1994;
26. PCT International Application WO 97/42956, published
November 20, 1997;
27. PCT International Application WO 98/51311, published
November 19, 1998;
28. PCT International Application WO 99/07695, published
February 18, 1999;
29. PCT International Application WO 99/48530, published
September 30, 1999;
30. European Patent Application No. EP 0 162 208, published
November 27, 1985;

Mohammad R. Marzabadi, et al.
Application No: Not Yet Known
Filed: Herewith
Page 5

31. European Patent Application 0 204 317, published December 10, 1986;
32. European Patent Application No. EP 0 234 830, published September 2, 1987;
33. European Patent Application No. EP 0 236 902, published September 16, 1987;
34. European Patent Application No. EP 0 237 347, published September 16, 1987;
35. European Patent Application No. EP 0 280 227, published August 31, 1988;
36. European Patent Application No. EP 0 400 665, published December 5, 1990;
37. European Patent Application No. EP 0 459 666, published December 4, 1991;
38. European Patent Application No. EP 0 622 369, published November 2, 1994;
39. European Patent Application No. EP 0 622 366, published November 2, 1994;
40. European Patent Application No. EP 0 627 427, published December 7, 1994;
41. French Patent Application No. 2 610 625 A, published August 12, 1998;

42. Japanese Patent No. 56-59778, issued May 23, 1981;
43. Japanese Patent No. 61-282367, published December 12, 1986;
44. Japanese Patent No. 62-87574, published April 22, 1987;
45. Japanese Patent No. 62-265271, published November 18, 1987;
46. Atwal, K.S., et al., "Synthesis of Substituted 1,2,3,4-Tetrahydro-6-Methyl-2-Thioxo-5-Pyrimidinecarboxylic Acid Esters," *Heterocycles* (1987) 26(5): 1189-1192;
47. Atwal, K.S., et al., "Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydropyrimidines," *Journal of Organic Chemistry* (1989) 54: 5898-5907;
48. Atwal, K.S., et al., "Dihydropyrimidine Calcium Channel Blockers: 2-Heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," *Journal of Medicinal Chemistry* (1990) 33(5): 1510-1515;
49. Atwal, K.S., et al., "Dihydropyrimidine Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," *Journal of Medicinal Chemistry* (1990), 33(9): 2629-2635;
50. Atwal, K.S., et al., "Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-

methyl-5-pyrimidene carboxylic Acid Esters as Orally Effective Antihypertensive Agents," *Journal of Medicinal Chemistry* (1991) 34(2): 806-811;

51. Barrio, et al., "A Direct Method For Preparation of 2-Hydroxyethoxymethyl Derivatives of Guanine, Adenine, and Cytosine," *Journal of Medicinal Chemistry* (1980) 23(5): 572-574;
52. Boer, R., et al., "(+)-Niguldipine binds with very high affinity to Ca^{2+} channels and to a subtype of α_1 -adrenoceptors," *European Journal of Pharmacology - Molecular Pharmacology Section* (1989) 172: 131-145;
53. Brown, et al., "Inhibitors of *Bacillus subtilis* DNA Polymerase III. 6-(Arylalkylamino)uracils and 6-Anilinouracils," *Journal of Medicinal Chemistry* (1977) 20(9): 1186-1189;
54. Cho H., et al., Regioselective synthesis of N-substituted dihydropyrimidine-2(1-H) or (3H)-One. *Tetrahedron Letters*, (1988) 29(42): 5405-5408;
55. Cho, H., et al., "Dihydropyrimidines: Novel Calcium Antagonists with Potent and Long-Lasting Vasodilative and Antihypertensive Activity," *Journal of Medicinal Chemistry* (1989) 32: 2399-2406;
56. D'Eletto, R.D. and Javitt, N.B., "Effect of Doxazosin on Cholesterol Synthesis In Cell Culture," *Journal of Cardiovascular Pharmacology* (1989) 13, Supp. 2: S1-S4;

57. Forray, et al., "The α_1 -Adrenergic Receptor That Mediates Smooth Muscle Contraction in Human Prostate Has The Pharmacological Properties of the Cloned Human α_{1c} Subtype," *Molecular Pharmacology* (1994) 45: 703-708;
58. Khanina, E.L., et al., Alkylation of derivatives of 2-oxo-4-phenyl-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxlic acid. *Chemical Abstracts* (1978) 89: 43319;
59. Mamaev, V.P. and Dubovenko, Z.D., Pyrimidines. XXI. 5-Substituted 2-hydroxy-4,6-diphenylpyrimidines. *Chemical Abstracts* (1970) 73: 77187;
60. McGrath, J.C., et al., "Alpha-Adrenoceptors: A Critical Review," *Medicinal Research Reviews* (1989) 9(4): 407-533;
61. Rovnyak, G.C., et al., "Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic Acid Esters. Potent Antihypertensive Agents," *Journal of Medicinal Chemistry* (1992) 35(17): 3254-3263;
62. Spiers, J.P., et al., "UK-52,046 (A Novel α_1 -Adrenoceptor Antagonist) and the Role of α -Adrenoceptor Stimulation and Blockade on Atrioventricular Conduction," *Journal of Cardiovascular Pharmacology* (1990) 16(5): 824-830;
63. Triggle, D.J., "Dihydropyrimidine Calcium Channel Blockers. 2,3-Substituted 4-Aryl-1,4-dihydro-6-methyl-5-pyrimidine-Carboxylic Acid Esters as Potent Mimics of Dihydropyridines," *Chemtracts- Organic Chemistry* (Jan./Feb. 1991) 68-72;

Mohammad R. Marzabadi, et al.
Application No: Not Yet Known
Filed: Herewith
Page 9

64. Wetzel, J.M., et al., "Discovery of α_{1a} -Adrenergic Receptor Antagonists Based on the L-Type Ca^{2+} Channel Antagonist Niguldipine" *Journal of Medicinal Chemistry* (1995) 38(10): 1579-1581;
65. Zhan, G.L., et al., "Bunazosin Reduces Intraocular Pressure By Increasing Uveoscleral Outflow In Rabbits," *Investigative Ophthalmology and Visual Science* (1993) 34(4): Abst. No. 1133-49, p. 928;
66. U.S. Patent No. 6,037,354, issued March 14, 2000, Patane, et al.; and
67. U.S. Patent No. 6,245,773, issued June 12, 2001, Wong, et al.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Mohammad R. Marzabadi, et al.
Application No: Not Yet Known
Filed: Herewith
Page 10

No fee, other than the enclosed fee of \$770.00 for filing the subject application, is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee be found necessary, authorization is hereby given to charge any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
212) 278-0400

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 62524-AA/JPW/MJW	U.S. Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Applicants: Mohammad R. Marzabadi, et al.	
									Filing Date: Herewith	Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate
	4	4	3	8	1	1	7	3/20/84	Cherkofsky et al.			
	4	6	8	4	6	5	5	8/4/87	Atwal , et al.			
	4	6	8	4	6	5	6	8/4/87	Atwal, et al.			
	4	6	8	4	6	5	3	8/4/87	Taylor, E.C., et al			
	4	7	0	3	1	2	0	10/27/87	Press, et al.			
	4	7	2	8	6	5	2	3/1/88	Atwal, et al.			
	4	8	4	5	2	1	6	7/4/89	Taylor, E.C., et al			
	4	8	5	5	3	0	1	8/8/89	Atwal et al.			
	4	8	8	2	3	3	4	11/21/89	Shih, et al.			
	4	9	0	2	7	9	6	2/20/90	Taylor et al.			
	4	9	4	6	8	4	6	8/7/90	Nomura et al.			
	5	1	3	4	1	4	5	7/28/92	Brouwer, et al.			
	5	1	4	9	8	1	0	9/22/92	Perrior, et al.			
	5	2	0	2	3	3	0	4/13/93	Atwal, et al.			
	5	2	5	0	5	3	1	10/5/93	Cooper, et al.			
	5	2	9	2	7	4	0	3/8/94	Burri, et al.			
	5	5	2	1	1	8	9	5/28/96	Boykin, et al.			
	5	5	4	1	1	8	6	7/30/96	Breu, et al.			
	5	5	0	0	4	2	4	3/19/96	Nagamine, et al.			
	5	5	9	4	1	4	1	1/14/97	Yuan, et al.			
	5	9	4	2	5	1	7	8/24/99	Nagarathnam, et al.			
	6	0	3	7	3	5	4	3/14/00	Patane et al.			
	6	2	4	5	7	7	3	6/12/01	Wong et al.			

FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation	
		9	2	0	0	7	4	1					Yes	No
		9	2	0	0	7	4	1	1/23/92	PCT				
		9	2	1	4	4	5	3	9/3/92	PCT				
		9	4	1	0	9	8	9	5/26/94	PCT				
		9	4	2	2	8	2	9	10/13/94	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Mohammad R. Marzabadi, et al.
Serial No.: Not Yet Known

Filed: Herewith

For: Selective Melanin Concentrating Hormone-1 (MCH1) Receptor Antagonists And Uses Thereof

Exhibit A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office						Atty. Docket No. 62524-AA/JPW/MJW	U.S. Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								Applicants: Mohammad R. Marzabadi, et al.	
								Filing Date: Herewith	Group Art Unit:

FOREIGN PATENT DOCUMENTS

		Document Number						Date	Country	Class	Subclass	Translation		
		9	7	4	2	9	5	6				Yes	No	
		9	7	4	2	9	5	6	11/20/97	PCT				
		9	8	5	1	3	1	1	11/19/98	PCT				
		9	9	0	7	6	9	5	2/18/99	PCT				
		9	9	4	8	5	3	0	9/30/99	PCT				
		1	6	2	2	0	8		11/27/85	EPO				
		2	0	4	3	1	7		12/10/86	EPO				
		2	3	4	8	3	0		9/2/87	EPO				
		2	3	6	9	0	2		9/16/87	EPO				
		2	3	7	3	4	7		9/16/87	EPO				
		2	8	0	2	2	7		8/31/88	EPO				
		4	0	0	6	6	5		12/5/90	EPO				
		4	5	9	6	6	6		12/4/91	EPO				
		6	2	2	3	6	9		11/2/94	EPO				
		6	2	2	3	6	6		11/2/94	EPO				
		6	2	7	4	2	7		12/7/94	EPO				
		2	6	1	0	6	2	5	8/12/88	French				
		5	6	5	9	7	7	8	5/23/81	Japanese				
		6	1	2	8	2	3	6	7	12/12/86	Japanese			
		6	2	8	7	5	7	4	4/22/87	Japanese				
		6	2	2	6	5	2	7	1	11/18/87	Japanese			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	U.S. Serial No. 09/899,635, filed July 5, 2001, Lagu, et al;
	Atwal, K.S. et al., "Synthesis of Substituted 1,2,3,4- Tetrahydro-6- Methyl-2-Thioxo-5-Pyrimidinecarboxylic Acid Esters," Heterocycles (1987) 26(5): 1189-1192;
	Atwal, K. S. et al., "Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydropyrimidines," Journal of Organic Chemistry (1989) 54: 5898-5907;

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 62524-AA/JPW/MJW	U.S. Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants: Mohammad R. Marzabadi, et al.	
		Filing Date: Herewith	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Atwal, K. S. et al., Dihydropyrimidines Calcium Channel Blockers: 2-Heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," <i>Journal of Medicinal Chemistry</i> (1990) 33(5): 1510-1515;
	Atwal, K.S. et al., "Dihydropyrimidines Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," <i>Journal of Medicinal Chemistry</i> (1990) 33(9):2629-2635;
	Atwal, K. S. et al., "Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidene carboxylic Acid Esters as Orally Effective Antihypertensive Agents," <i>Journal of Medicinal Chemistry</i> (1991) 34(2) : 806-811;
	Barrio, et al., "A Direct Method For Preparation of 2-Hydroxyethoxymethyl Derivatives of Guanine, Adenine, and Cytosine," <i>Journal of Medicinal Chemistry</i> (1980) 23(5):572-574;
	Boer, R., et al., "(+)-Niguldipine binds with very high affinity to Ca^{2+} channels and to a subtype of α_1 -adrenoceptors," <i>European Journal of Pharmacology - Molecular Pharmacology Section</i> (1989) 172: 131-145;
	Brown, et al., "Inhibitors of <i>Bacillus subtilis</i> DNA Polymerase III. 6-(Arylalkylamino)uracils and 6-Anilinouracils," <i>Journal of Medicinal Chemistry</i> (1997) 20(9): 1186-1189;
	Cho H., Takeuchi Y., Ueda M., and Mizuno A. Regioselective synthesis of N-substituted dihydropyrimidine-2 (1-H) or (3H)-One. <i>Tetrahedron Letters</i> , Vol. 29 (42) : 5405-5408, 1988;
	Cho, H. et al., "Dihydropyrimidines: Novel Calcium Antagonists with Potent and Long-Lasting Vasodilative and Antihypertensive Activity," <i>Journal of Medicinal Chemistry</i> (1989) 32: 2399-2406;
	D'Eletto, R. D. and Javitt, N.B., "Effect of Doxazosin on Cholesterol Synthesis In Cell Culture," <i>Journal of Cardiovascular Pharmacology</i> (1989) 13, Supp. 2: S1-S4;
	Forray et al., "The α_1 -Adrenergic Receptor That Mediates Smooth Muscle Contraction in Human Prostate Has The Pharmacological Properties of the Cloned Human α_{1c} Subtype," <i>Molecular Pharmacology</i> (1994) 45: 703-708;
	Khanina, E. L. et al., Alkylation of derivatives of 2-oxo-4-phenyl-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid. <i>Chemical Abstracts</i> 89: 43319 (1978);
	Mamaev, V.P. and Dubovenko, Z.D., Pyrimidines. XXI. 5-Substituted 2-hydroxy-4,6-diphenylpyrimidines. <i>Chemical Abstracts</i> 73: 77187 (1970);
EXAMINER	DATE CONSIDERED

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 62524-AA/JPW/MJW	U.S. Serial No. Not Yet Known
		INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants: Mohammad R. Marzabadi, et al.	
				Filing Date: Herewith	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	McGrath, J. C. et al., "Alpha-Adrenoceptors: A Critical Review," <i>Medicinal Research Reviews</i> (1989) 9(4): 407-553;
	Rovnyak, G. C. et al., "Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic Acid Esters. Potent Antihypertensive Agents," <i>Journal of Medicinal Chemistry</i> (1992) 35(17): 3254-3263;
	Spiers, J. P. et al., "UK-52,046 (A Novel α_1 -Adrenoceptor Antagonist) and the Role of α -Adrenoceptor Stimulation and Blockade on Atrioventricular Conduction," <i>Journal of Cardiovascular Pharmacology</i> (1990) 16(5): 824-830;
	Triggle, D. J., "Dihydropyrimidine Calcium Channel Blockers. 2.3-Substituted 4-Aryl-1, 4-dihydro-6-methyl-5-pyrimidine-Carboxylic Acid Esters as Potent Mimics of Dihydropyridines," <i>Chemtracts-Organic Chemistry</i> (Jan./Feb. 1991) 68-72;
	Wetzel, J. M., et al., "Discovery of α_{1a} -Adrenergic Receptor Antagonists Based on the L-Type Ca ²⁺ Channel Antagonist Niguldipine" <i>Journal of Medicinal Chemistry</i> (1995) 38(10): 1579-1581; and
	Zhan, G. L. et al., "Bunazosin Reduces Intraocular Pressure By Increasing Uveoscleral Outflow In Rabbits," <i>Investigative Ophthalmology and Visual Science</i> (1993) 34(4): Abst. No. 1133-49, p. 928.
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.